Despite this, more recently it was reported another CNL patient with mutations in CSF3R and SETBP1, treated with ruxolitinib, showing clonal evolution with reduction of the CSF3R and SETBP1 mutations allele burden [114]. This evidence concerns the gene SETBP1 and chronic neutrophilic leukemia.